摘要
目的:采用Meta分析方法评价痰热清注射液联合抗菌药治疗老年社区获得性肺炎(CAP)的临床疗效及安全性。方法:计算机检索CNKI、VIP、Wan Fang Data、Sino Med、Pub Med、the Cochrane Library和Embase数据库中痰热清注射液联合抗菌药治疗CAP的随机对照试验(RCTs),检索时限均为建库至2018年5月31日,由两名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用Rev Man 5. 3软件进行Meta分析。结果:共纳入23个RCTs,累计受试者2 207例。Meta分析结果显示:对比抗菌药单用或抗菌药辅以常规治疗,痰热清注射液联合抗菌药治疗可有效提高老年CAP患者临床总有效率[RR=1. 16,95%CI(1. 12,1. 19),P <0. 000 01],有利于缩短退热时间、肺部啰音消失时间、咳嗽消失时间、降低C-反应蛋白(CRP)含量和白细胞(WBC)计数。安全性方面,8篇文献报道无明显药品不良反应,9篇报道了药品不良反应的具体情况,且均未出现严重的药品不良反应情况,其余6篇未对药品不良反应发生情况进行报道。结论:痰热清注射液联合抗菌药在治疗老年CAP方面具有较好的疗效,安全性尚可,但仍然需要进行进一步研究探讨。
Objective: To systematically evaluate the clinical efficacy and safety of Tanreqing injection combined with antibiotics in treatment of elderly community-acquired pneumonia( CAP). Methods: Randomized controlled trials( RCTs) regarding CAP treated by Tanreqing injection combined with antibiotics were searched in CNKI,VIP,Wan Fang Data,Sino Med,Pub Med,the Cochrane Library and Embase from inception to May 31 st,2018. Two reviewers independently screened literature,extracted data and assessed the risk of bias of included studies. Meta-analysis was performed by Reve Man 5. 3 software. Results: There were 23 RCTs included,involving 2 207 participants. According to the Meta-analysis,compared with antibiotics alone,Tanreqing injection combined with antibiotics could improve total effective rate( RR =1. 16,95% CI 1. 12 to 1. 19,P < 0. 000 01). Besides,Tanreqing injection combined with antibiotics could shorten the patients’ antifebrile time,the pulmonary rales disappeared time and the disappearance time of cough. What’s more,it could lower the level of CRP and WBC. As for the security,8 articles reported that there were no adverse drug reactions( ADRs)/adverse drug events( ADEs) in the studies,9 articles reported the details of ADRs. And the rest had no illustrations for it. Conclusion: Tanreqing injection combined with antibiotics is more effective than conventional medicine alone in treatment of CAP,the safety is good. However,it is still necessary with further study for safety of its compatibility with western medicine.
作者
黄星月
段笑娇
吴嘉瑞
林茜
张思旋
王凯欢
田学浩
郑捷文
Huang Xingyue;Duan Xiaojiao;Wu Jiarui;Lin Xi;Zhang Sixuan;Wang Kaihuan;Tian Xuehao;Zheng Jiewen(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing102488,China)
出处
《药物流行病学杂志》
CAS
2018年第12期777-784,共8页
Chinese Journal of Pharmacoepidemiology
基金
2018国家级大学生创新创业训练计划项目(编号:201810026059)
国家自然科学基金项目(编号:81473547
81673829)
